Dr. Reddy's Laboratories Ltd. Sponsored ADR (NSE:DRREDDY) saw mixed results as Q1 revenue of ₹8,070.5cr and EBITDA of ₹1,009cr were hit by a ₹240cr provisional semaglutide API charge and 35% North America decline, while FDA cleared a Rituxan biosimilar and Thailand approved Nuzolvence.Previous Week…
Revenue declined 5.6% year-over-year due to lower lenalidomide sales and semaglutide API issues, but base business delivered double-digit growth across geographies. EBITDA margin was 12.5%, with guidance maintained near 20% as semaglutide supply is expected to resume in November. Strong growth in I…
Double-digit base business growth was achieved across all geographies, with strong new product launches and favorable forex, but results were impacted by semaglutide API issues and lower lenalidomide sales. Net cash surplus stood at ₹3,058 Cr, and ROCE was 5.3%.Original document: Dr. Reddy's Labora…
Shares of Dr. Reddy's Laboratories (NSE:DRREDDY) jumped about 4% after the FDA closed a Pre-License Inspection at its Bachupally biologics site with a Form 483 noting seven observations, as analysts eye a potential Q4 2026–27 Abatacept biosimilar launch that could boost FY28–29 earnings amid resolv…
Emkay Global Financial' research report on Dr ReddysDr Reddy’s’ Form 20-F disclosures indicate that gRevlimid sales in FY26 were closer to our base-case estimate (~$300mn). However, assuming muted growth in the company’s base oncology portfolio since FY22, gRevlimid contribution would have been hig…
By Bharath RajeswaranIndian shares slipped on Monday, pausing after their longest weekly winning streak of 2026, as concerns over a weak monsoon blunted relief from easing Middle East tensions and lower crude prices.The retreat also reflected fatigue after a three-week rally, with analysts saying s…
Dr Reddy's Laboratories shares extended their gaining streak to the sixth consecutive session on Monday, emerging among the top performers on the Nifty50 index.The stock gained after the US drug regulator completed an inspection at the company's biologics facility in Bachupally, Hyderabad, and issu…
By Bharath RajeswaranIndian shares were steady on Monday after posting their longest weekly winning streak of 2026 in the last session, as the U.S. and Iran agreed to halt recent hostilities, tempering concerns of an escalation in the ongoing conflict.The benchmark Nifty 50 NSE:NIFTY rose 0.24% to…
Shares of Dr. Reddy's Laboratories, the Hyderabad-based drugmaker are trading with gains of 5% on Monday, June 29, despite the United States Food and Drug Administration issuing seven observations to its biologics manufacturing facility at Bachupally in Hyderabad.This is the sixth straight day of g…
Several stocks are likely to remain in focus on June 29 amid key corporate developments, including regulatory updates, acquisitions, merger proposals, project wins and real estate expansion.Dr Reddy's Laboratories shares gained 4 percent after the US Food and Drug Administration (US FDA) completed…
